Supplementary Figure 1 from The MDM2–p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study
Year: 2024
Type: supplementary-materials
Abstract: GDF-15 fold change from baseline for dose-escalation cohorts receiving BI 907828 D1q3w and BI 907828 D1D8q4w
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402855732